U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07712939) titled 'A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases' on July 08.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
Study Start Date: July 20
Study Type: INTERVENTIONAL
Condition:
Healthy Participants Study
Rheumatoid Arthritis
Sjogren's Syndrome
Intervention:
BIOLOGICAL: CND319
CND319
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Candid Therapeutics
Published by HT Digital Conte...